Incannex Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price Standards

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 22 2025

0mins

Source: Globenewswire

Nasdaq Compliance Extension: Incannex Healthcare has received a 180-day extension from Nasdaq to meet the minimum bid price requirement, allowing until April 20, 2026, to maintain a closing bid price of at least $1.00 per share.
Operational Progress: The company has successfully delivered two Phase 2 clinical data packages this year, strengthening its development platform and positioning for future growth.
Commitment to Compliance: Incannex is dedicated to regaining compliance with Nasdaq listing requirements and plans to monitor its share price closely, potentially utilizing a reverse stock split if necessary.
Innovative Drug Development: Incannex is focused on developing combination therapies for chronic conditions, with ongoing clinical programs targeting obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.